Posted 4th October 2017 by Jane Williams
Interest in microbiota has reached all areas of human health and disease. As a result, the therapeutic potential of probiotics has expanded. 2013 saw a surge of investment into prebiotics and probiotics, coinciding with an increase in microbiome funding. In the last decade, investment has quadrupled.
Posted 25th September 2017 by Jane Williams
Colorectal cancer (CRC) is the result of a series of histopathological changes starting with the appearance of outbreaks of aberrant crypts (AC) in the colon and generally leading to adenocarcinoma. CRC is one of the third most common diagnosed cancers in western countries.
Posted 28th August 2017 by Jane Williams
Image credit: NIAID, Flickr, licensed under CC BY 2.0
Autoimmune diseases are an outcome of a dysfunctional immune system. Most common autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are polygenic autoimmune disorders. However, several monogenic autoimmune disorders have been identified.
Posted 14th August 2017 by Jane Williams
Fermentation, commonly used to preserve foods, has become the latest “gut health” phenomenon. Fermented foods contain an array of microorganisms which have the potential to confer health benefits to individuals that ingest them. In fact, there are several fermented beverages and foods currently on the market purported to be health-promoting; not all of which are equally beneficial.
Posted 2nd August 2017 by Jane Williams
Google search volume for the term ‘probiotics’ from 2004 – 2016. Data source: Google Trends
Microbiota has been associated with almost all aspects of human health and disease. Subsequently, the potential applications of probiotics broadened. However, health claim regulation has had a major impact on the probiotic market, particularly in the EU.
Posted 16th June 2017 by Jane Williams
This article was originally published by the California Dairy Research Foundation, May 2017, and is published with permission.
Among all the options for probiotics on store shelves, how can end-users spot a high-quality product? In today’s U.S. market, it’s not easy.
Posted 9th June 2017 by Jane Williams
Robert Osgood, Program Director and Associate Professor at the Rochester Institute of Technology, was interviewed about his work on the oral probiotic, Streptococcus salivarius K12 BLIS.